All In Biotech

Drug Trial Radar · NCT07494799

Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear

A Prospective Study on the Efficacy of Different Interventions for Progressive Myopia in Children After Orthokeratology Lens Wear

Last checked: Nov 20, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

3,890

Planned (sponsor's estimate)

Start

Apr 1, 2026

Primary completion

May 1, 2026

Study completion Apr 1, 2027

Sponsor

Lead sponsor
Tianjin Medical University Eye HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 27, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 8 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Myopia has emerged as a significant concern impacting the visual health of children and adolescents on a global scale. According to research conducted by Holden BA et al., it is projected that by the year 2050, the worldwide prevalence of myopia and high myopia will experience a substantial increase, affecting approximately 5 billion and 1 billion individuals, respectively, with particularly high prevalence rates observed in East Asia\[1\]. The persistent rise in myopia incidence, coupled with the escalation of complications associated with high myopia, is anticipated to exert complex socio-economic repercussions \[2\]. Consequently, the prevention of myopia onset and the management of axial length elongation have become critically important \[3\]. Orthokeratology (Ortho-K) is a procedure that involves the overnight application of specially designed reverse geometry rigid gas permeable contact lenses to achieve temporary corneal reshaping and reduce myopia during the day\[4,5\]. In children with mild to moderate myopia, Ortho-K has demonstrated visual correction efficacy ranging from 80% to 92%\[6,7\]. Nonetheless, its efficacy in controlling myopia progression may not match its corrective efficacy. The therapeutic effect of Ortho-K in decelerating axial elongation is reported to range from 43% to 63%. Despite the use of Ortho-K, approximately 15% of children continue to exhibit rapid axial elongation exceeding 0.36 mm per year.\[8,9\]. In recent years, adjunctive interventions such as low-concentration atropine eye drops, modification of the back optical zone diameter (BOZD) of orthokeratology (Ortho-K) lenses, and low-level red-light therapy (RLRL) have been proposed to augment the myopia control efficacy of Ortho-K. Zhao et al. \[10\] reported that after one year of treatment with either atropine orthokeratology (AOK) or Ortho-K lenses in children aged 5-14 years, the axial length (AL) increased by 0.14 mm and 0.29 mm, respectively. Another study involving children aged 8-12 years \[11\] demonstrated that after one year of treatment, the AOK group exhibited a 17% reduction in AL growth (0.20 mm vs. 0.24 mm). Research conducted by Xiong et al. \[12\] indicated that for children whose eyes elongated by at least 0.50 mm within one year of Ortho-K wear, the combination of RLRL therapy with Ortho-K significantly reduced axial elongation compared to Ortho-K alone. Additional studies have suggested that decreasing the BOZD can enhance the extent and degree of mid-peripheral corneal steepening, thereby decelerating axial elongation \[13-15\]. Most existing studies primarily compare a single intervention against a control group, thereby lacking direct "head-to-head" comparisons. Traditional meta-analyses are limited to comparing two interventions at a time and often fail to assess multiple treatments concurrently. Consequently, most meta-analyses offer only statistical insights into the efficacy of individual interventions. Clinically, it is common to combine two or more interventions to treat myopia, particularly in cases of rapidly progressive myopia. Previous research has indicated that combined interventions may have additive effects in the prevention and control of myopia; however, these findings require further empirical validation. This study employs a retrospective approach to evaluate the efficacy of various treatment strategies in managing axial elongation in children aged 8-12 years who experience rapid axial progression following Ortho-K lens wear. The objective is to provide a scientific foundation for the development of personalized myopia control plans.

Conditions

  • Progressive Myopia
  • Pediatric Myopia
  • Orthokeratology-related Myopia Progression

Interventions

  • OK Lens Continuation GroupDevice

    Continue wearing original orthokeratology lenses with unchanged parameters, follow-up every 6 months.

  • OK Lens + 0.01% Atropine GroupDrug

    Continue OK lenses + 0.01% atropine sulfate eye drops once daily at bedtime.

  • OK Lens with Reduced Optical Zone GroupDevice

    Wear OK lenses with reduced optical zone diameter (adjusted by 0.5mm from original parameters).

  • OK Lens + Low-Intensity Red Light GroupDevice

    Continue OK lenses + low-intensity red light therapy (630nm, 6 minutes daily).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Axial Length from Baseline at 12 MonthsTime frame: 12 Months
  2. Change in Axial Length from Baseline at 12 MonthsTime frame: 12 Months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.